Cardiovascular Outcomes Trials
Response by Bhatt et al to Letter Regarding Article, “REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States
Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE-IT trial: why these results usher in a new era in dyslipidaemia therapeutics
Reduction in First and Total Ischemic Events with Icosapent Ethyl Across Baseline Triglyceride Tertiles
REDUCE-IT: Residual Cardiovascular Risk in Statin-Treated Patients with Elevated Triglycerides: Now We Can REDUCE-IT!